SCHEMBL892318

SCHEMBL892318

Cc1ccc(NC(=O)c2cncs2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.72
RAB9A P51151 8/20 0.58
NPC1 O15118 7/20 0.58
SMN1; SMN2 Q16637 7/20 0.58
NAMPT P43490 2/20 0.54
GRM4 Q14833 1/20 0.50
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.48
KDM4E B2RXH2 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MAPT P10636 4/20 0.47
LMNA P02545 1/20 0.47
ESRRG P62508 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6604871 0.84 KMT2A (1.00) KMT2ARAB9ANPC1NAMPTGRM4
SCHEMBL892780 0.83 KMT2A (0.71) KMT2ARAB9ANPC1SMN1; SMN2NAMPT
SCHEMBL28099856 0.80 KMT2A (0.51) KMT2ARAB9ANPC1SMN1; SMN2GRM4
SCHEMBL15886292 0.80 KMT2A (0.72) KMT2ARAB9ANPC1SMN1; SMN2NAMPT
SCHEMBL16160184 0.78 KMT2A (0.56) KMT2ARAB9ANPC1NAMPTGRM4
SCHEMBL16735818 0.78 KMT2A (0.49) KMT2ARAB9ANPC1SMN1; SMN2NAMPT
SCHEMBL30909377 0.77 KMT2A (0.62) KMT2ARAB9ANPC1SMN1; SMN2NAMPT
SCHEMBL19205386 0.76 KMT2A (0.56) KMT2ARAB9ASMN1; SMN2MAPTLMNA
SCHEMBL6605576 0.76 HPGD (0.54) KMT2ARAB9ANPC1SMN1; SMN2GRM4
SCHEMBL1540045 0.76 LCK (0.50) KMT2ASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases REMYND (BE) 2019-02-21 US disclosed
CN-103998434-B Thiazole and application thereof as DHODH inhibitor 华东理工大学 2016-10-12 CN disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN KMT2A 2251/4885RAB9A 1779/4885NPC1 704/4885
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases SNCA, MAPT, NLN KMT2A 2251/4885RAB9A 1779/4885NPC1 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.